JMT106 Injection in the Treatment of Advanced Solid Tumors

Summary

This study is the first-in-human Phase I study of JMT106 injection, comprising two phases: Dose escalation with backfill and cohort expansion. The planned study population consists of subjects with advanced solid tumors. The objective is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of JMT106 injection as monotherapy in participants with advanced solid tumors

Timeline

Start

2025-09-25

Primary completion

2026-11-05

Completion

2028-11-15

Drugs

Indications